<?xml version="1.0" encoding="UTF-8"?>
<p>In China and France, small studies provide some indications of possible benefits of chloroquine phosphate against pneumonia caused by COVID-19, but need confirmation through randomized trials (
 <xref rid="ref9" ref-type="bibr">9</xref>). Chloroquine also has been shown to have anti-viral as well as immune-modulating properties. This drug also showed 1.13 Î¼M at half-maximal concentration against SARS-CoV-2 and blocked viral infection by increasing the endosomal 
 <italic>p</italic>H required for viral fusion (
 <xref rid="F2" ref-type="fig">Fig. 2</xref>) (
 <xref rid="ref30" ref-type="bibr">30</xref>). Azithromycin has been suggested to act in combination with Chloroquine/hydroxychloroquine against SARs-CoV-2 (
 <xref rid="ref31" ref-type="bibr">31</xref>). Several 
 <italic>in vitro</italic> studies reported the anti-viral activity of Chloroquine and hydroxychloroquine against SARS-CoV-2. At present, there is insufficient 
 <italic>in vivo</italic> evidence to recommend their use for the current pandemic outside of clinical trials. Further high-quality studies are urgently needed to provide guidance to clinicians and policymakers.
</p>
